Serotonergic involvement in methamphetamine-induced locomotor activity: A detailed pharmacological study
► We assessed serotonergic and dopaminergic effects on the methamphetamine-induced hyperactivity. ► Modulation was observed by 5-HT depletion, certain 5-HT receptor ligands and dopamine ligands. ► Data suggest key 5-HT involvement with potential downstream dopamine involvement. The mechanism by whic...
Gespeichert in:
Veröffentlicht in: | Behavioural brain research 2011-06, Vol.220 (1), p.9-19 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | ► We assessed serotonergic and dopaminergic effects on the methamphetamine-induced hyperactivity. ► Modulation was observed by 5-HT depletion, certain 5-HT receptor ligands and dopamine ligands. ► Data suggest key 5-HT involvement with potential downstream dopamine involvement.
The mechanism by which the psychostimulant methamphetamine (METH) increases locomotor activity may be attributable to indirect activation of serotonin (5-HT) and dopamine (DA) receptors. In the present study, the ability of the serotonin reuptake inhibitor fluvoxamine, 5-HT
1A, 5-HT
1B, 5-HT
2A and 5-HT
2C receptor antagonists WAY100635, GR127935, M100907 and SB242084, and the 5-HT
2C receptor agonists WAY163909 and Ro 60-0175 or the 5-HT synthesis inhibitor para-chlorophenylalanine (pCPA) to alter METH-induced hyperactivity was analysed. Further, for comparative purposes, the involvement of the DA D
1 and D
2 receptor antagonists SCH23390 and haloperidol, D
2 partial agonists terguride, (−)3PPP and aripiprazole and finally clozapine were assessed. Doses of pCPA that attenuated 5-HT levels reduced METH activity. The 5-HT
1B antagonist GR127935 had no effect on METH-induced locomotor activity but blocked that induced by MDMA. The 5-HT
1A antagonist WAY100635 reduced activity but this did not reach significance. In contrast, M100907 (minimal effective dose; MED
=
0.125
mg/kg), WAY163909 (MED
=
3
mg/kg), Ro 60-0175 (MED
=
3
mg/kg), haloperidol (MED
=
0.1
mg/kg), clozapine (MED
=
5
mg/kg), aripiprazole (MED
=
1
mg/kg), (−)3PPP (MED
=
3
mg/kg), terguride (MED
=
0.2
mg/kg) and SCH23390 (MED
=
0.001325
mg/kg) attenuated METH-induced locomotor activity. Administration of 20
mg/kg fluvoxamine attenuated, while SB242084 (MED
=
0.25
mg/kg) potentiated METH-induced activity.
These results contribute significantly to the understanding of the mechanism of action of this psychostimulant and suggest for the first time, that METH-induced locomotor stimulation is modulated by 5-HT
2A and 5-HT
2C receptors, but demonstrate that 5-HT
1B receptors are not directly involved. The involvement of the dopaminergic system was also demonstrated. |
---|---|
ISSN: | 0166-4328 1872-7549 |
DOI: | 10.1016/j.bbr.2011.01.026 |